

Maria Mercedes Santoro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5376425/publications.pdf>

Version: 2024-02-01

122
papers

2,190
citations

318942

23
h-index

355658

38
g-index

122
all docs

122
docs citations

122
times ranked

3072
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. <i>Reviews in Medical Virology</i> , 2022, 32, e2261.	3.9	23
2	Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106492.	1.1	6
3	Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients. <i>Scientific Reports</i> , 2022, 12, 1374.	1.6	1
4	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. <i>Microbiology Spectrum</i> , 2022, 10, e0273221.	1.2	35
5	Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study. <i>HIV Medicine</i> , 2022, 23, 629-638.	1.0	3
6	Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches. <i>Infection, Genetics and Evolution</i> , 2022, 101, 105294.	1.0	1
7	Impact of pre-existing drug resistance on virological efficacy of single-tablet regimens in people living with HIV. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106636.	1.1	1
8	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106252.	1.1	13
9	Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted darunavir in clinical practice. <i>HIV Medicine</i> , 2021, 22, 519-525.	1.0	6
10	Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1277-1285.	1.3	14
11	Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY study in Cameroon. <i>HIV Medicine</i> , 2021, 22, 567-580.	1.0	10
12	The impact of DAA-mediated HCV eradication on CD4 ⁺ and CD8 ⁺ T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 779-786.	1.0	12
13	Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. <i>Viruses</i> , 2021, 13, 743.	1.5	2
14	HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol. <i>PLoS ONE</i> , 2021, 16, e0253587.	1.1	1
15	Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study. <i>Viruses</i> , 2021, 13, 1403.	1.5	3
16	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3272-3279.	1.3	0
17	High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 102, 115574.	0.8	3
18	Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 163-169.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa456.	0.4	16
20	Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. <i>Clinical Microbiology and Infection</i> , 2020, 27, 1038.e1-1038.e6.	2.8	0
21	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	1.6	11
22	Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. <i>PLoS ONE</i> , 2020, 15, e0235958.	1.1	6
23	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , 2020, 12, 791.	1.5	11
24	First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 143.	1.5	14
25	Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon. <i>AIDS Research and Therapy</i> , 2020, 17, 14.	0.7	8
26	Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106027.	1.1	10
27	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2547-2553.	1.3	11
28	Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1778-1786.	1.3	11
29	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, e24-e28.	0.9	3
30	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1026-1030.	1.3	20
31	HIV MDR is still a relevant issue despite its dramatic drop over the years. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1301-1310.	1.3	13
32	HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , 2020, 9, 93.	2.5	4
33	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020, 53, 100721.	6.5	80
34	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). <i>Chemical Biology and Drug Design</i> , 2019, 93, 50-59.	1.5	3
35	Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study). <i>BMC Pediatrics</i> , 2019, 19, 226.	0.7	9
36	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019, 19, 1291.	1.2	4

#	ARTICLE	IF	CITATIONS
37	SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e699-e700.	1.8	0
38	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	1.2	46
39	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. <i>Journal of Clinical Virology</i> , 2019, 117, 61-67.	1.6	24
40	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	0.8	18
41	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	0.6	4
42	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019, 116, 23-28.	1.6	11
43	HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. <i>BMC Infectious Diseases</i> , 2019, 19, 246.	1.3	14
44	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , 2019, 55, 290-297.	0.7	0
45	Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat". <i>AIDS Research and Therapy</i> , 2019, 16, 36.	0.7	32
46	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 614-617.	1.3	23
47	Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. <i>New Microbiologica</i> , 2019, 42, 69-80.	0.1	0
48	Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	0.6	10
49	Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. <i>Medicine (United States)</i> , 2018, 97, e0176.	0.4	13
50	Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	1.6	2
51	Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2480-2484.	1.3	15
52	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	1.6	19
53	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA >500 copies/mL. <i>Infection</i> , 2017, 45, 521-528.	2.3	10
54	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017, 18, 225-235.	2.7	28

#	ARTICLE	IF	CITATIONS
55	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	2.8	11
56	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	1.3	15
57	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	1.8	18
58	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ L After Reaching (or Starting From) Values Higher than 350 Cells/ μ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 417-422.	0.9	2
59	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 465-471.	0.9	4
60	Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. <i>HIV Medicine</i> , 2017, 18, 21-32.	1.0	9
61	HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. <i>Current HIV Research</i> , 2017, 15, 66-73.	0.2	4
62	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017, 19, .	0.5	5
63	High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. <i>Current HIV Research</i> , 2016, 14, 165-171.	0.2	29
64	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	0.9	39
65	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw512.	1.3	8
66	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 7, 1-7.	0.9	3
67	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , 2016, 82, 94-100.	1.6	35
68	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	1.3	13
69	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	4.6	217
70	Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. <i>Aids</i> , 2016, 30, 731-741.	1.0	12
71	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
72	Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 329-333.	0.5	4

#	ARTICLE	IF	CITATIONS
73	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
74	HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. Current HIV Research, 2016, , .	0.2	1
75	P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing. Journal of Hepatology, 2015, 62, S688.	1.8	1
76	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS ONE, 2015, 10, e0140877.	1.1	7
77	Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. PLoS ONE, 2015, 10, e0135325.	1.1	21
78	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 2015, 16, 297-306.	1.0	9
79	Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. Digestive and Liver Disease, 2015, 47, e48.	0.4	0
80	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. Journal of Clinical Microbiology, 2015, 53, 2935-2941.	1.8	6
81	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. Journal of Antimicrobial Chemotherapy, 2015, 70, 1865-1873.	1.3	23
82	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. Journal of Infection, 2015, 70, 288-298.	1.7	11
83	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. New Microbiologica, 2015, 38, 443-90.	0.1	6
84	Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with aripla vs. tenofovirâ€Š+â€Šemtricitabine/lamivudineâ€Š+â€Šefavirenz administered on a multiple tablet therapy. Aids, 2014, 28, 2531-2539.	1.0	30
85	Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels. Clinical Infectious Diseases, 2014, 58, 1156-1164.	2.9	67
86	Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release. Digestive and Liver Disease, 2014, 46, e53.	0.4	0
87	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. Journal of Infection, 2014, 69, 408-410.	1.7	2
88	A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-NaÃve Patients Starting a First-Line HAART. PLoS ONE, 2014, 9, e105853.	1.1	9
89	Drugâ€Šresistance development differs between <scp>HIV</scp>â€Šinfected patients failing firstâ€Šline antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Medicine, 2013, 14, 571-577.	1.0	7
90	HIV-1 Genetic Variability and Clinical Implications. , 2013, 2013, 1-20.		115

#	ARTICLE	IF	CITATIONS
109	Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 336-344.	0.9	32
110	Use of novel antiretroviral agents in rescue regimens: A case of early virological failure to raltegravir. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 237-239.	1.5	1
111	Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients. <i>Infection</i> , 2009, 37, 233-243.	2.3	9
112	Dynamics of NRTI Resistance Mutations during Therapy Interruption. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 57-64.	0.5	11
113	Non-B HIV Type 1 Subtypes among Men Who Have Sex with Men in Rome, Italy. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 157-164.	0.5	18
114	Short Communication: Characterization of Drug-Resistance Mutations in HIV Type 1 Isolates from Drug-Naive and ARV-Treated Patients in Bulgaria. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1133-1138.	0.5	15
115	The HIV Type 1 Epidemic in Bulgaria Involves Multiple Subtypes and Is Sustained by Continuous Viral Inflow from West and East European Countries. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 771-779.	0.5	34
116	Specific Enfuvirtide-Associated Mutational Pathways in HIV-1 Gp41 Are Significantly Correlated With an Increase in CD4+Cell Count, Despite Virological Failure. <i>Journal of Infectious Diseases</i> , 2008, 197, 1408-1418.	1.9	38
117	Viro-Immunologic Response to Ritonavir-Boosted or Unboosted Atazanavir in a Large Cohort of Multiply Treated Patients: The CARE Study. <i>AIDS Patient Care and STDs</i> , 2008, 22, 7-16.	1.1	18
118	Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. <i>Journal of Virology</i> , 2007, 81, 11507-11519.	1.5	62
119	Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. <i>Journal of Virology</i> , 2006, 80, 7186-7198.	1.5	64
120	Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. <i>New Microbiologica</i> , 2006, 29, 89-100.	0.1	3
121	Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2015-2025.	1.4	58
122	High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. <i>Journal of Virology</i> , 2005, 79, 10718-10729.	1.5	50